Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Prima BioMed releases final data from phase II ovarian cancer study of CVac

May 20, 2015

Preliminary first-in-human phase I results presented for RBL-001/RBL-002

May 19, 2015

Sacituzumab govitecan awarded FDA fast track designation for NSCLC

May 18, 2015

Preliminary phase I trial results presented on DC vaccination therapy for AML

May 18, 2015

Vaccination with FSPs shows potential for the treatment of MSI-H CRC

May 18, 2015

GlycoOptimization technology shows promising results for cancer therapy

May 15, 2015

DI-B4 monoclonal antibody well-tolerated in NHL and CLL patients

May 15, 2015

Phase I results for CV-9104

May 15, 2015

Researchers report phase II results of VXM-01 in pancreatic cancer patients

May 14, 2015

FDA accepts IND for Aspyrian's RM-1929 for head and neck cancer

May 14, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...